Dicerna Pharmaceuticalsincis A Biopharmaceutical Company Based In Lexingtonmassachusettsfounded In 2007As A Wholly Owned Subsidiary Of Novo Nordiskdicerna Specializes In Developing Rna Interferencernaitherapies Using Its Proprietary Galxca C And Galxc Plusa C Technologiesthese Technologies Allow For The Selective Silencing Of Genes Associated With Various Diseasesproviding Potential Treatments For Both Rare And Common Conditions The Company Focuses On Rnai Based Therapiesinitially Targeting Disease Causing Genes In The Liver And Expanding To Other Tissues And Cell Typesdicerna S Pipeline Includes Treatments For Lymphomasolid Tumorscardiometabolic Diseasesviral Infectionschronic Liver Conditionsneurodegenerative Diseasesand Paindicerna Has Formed Collaborations With Several Prominent Pharmaceutical Companiesincluding Novo Nordiskrocheand Eli Lillyemphasizing Its Commitment To Advancing Rnai Technology In The Healthcare Sector
